Adial Pharmaceuticals Inc (NASDAQ:ADIL) — Market Cap & Net Worth
Market Cap & Net Worth: Adial Pharmaceuticals Inc (ADIL)
Adial Pharmaceuticals Inc (NASDAQ:ADIL) has a market capitalization of $9.43 Million ($9.43 Million) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27327 globally and #5652 in its home market, demonstrating a -24.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adial Pharmaceuticals Inc's stock price $5.00 by its total outstanding shares 2188469 (2.19 Million). Also see Adial Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Adial Pharmaceuticals Inc Market Cap History: 2018 to 2026
Adial Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows change from $280.12 Million to $10.94 Million (-30.90% CAGR). Also see ADIL cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Adial Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.00% | #779 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.00% | #2520 of 3165 |
Weight: Adial Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adial Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adial Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ADIL share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ADIL by Market Capitalization
Companies near Adial Pharmaceuticals Inc in the global market cap rankings as of September 15, 2026. Review tangible net worth ratio of Adial Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Adial Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Adial Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Adial Pharmaceuticals Inc's market cap moved from $280.12 Million to $ 10.94 Million, with a yearly change of -30.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.94 Million | +2172.73% |
| 2025 | $481.46K | -78.22% |
| 2024 | $2.21 Million | -45.70% |
| 2023 | $4.07 Million | -65.40% |
| 2022 | $11.76 Million | -92.04% |
| 2021 | $147.72 Million | +58.82% |
| 2020 | $93.01 Million | -29.46% |
| 2019 | $131.86 Million | -52.93% |
| 2018 | $280.12 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Adial Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.43 Million USD |
| MoneyControl | $9.43 Million USD |
| MarketWatch | $9.43 Million USD |
| marketcap.company | $9.43 Million USD |
| Reuters | $9.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more